All In Biotech

Drug Trial Radar · NCT06892379

A Study of HS-20110 in Participants With Advanced Solid Tumors

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20110 in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

631

Planned (sponsor's estimate)

Start

Feb 26, 2025

Primary completion

Dec 31, 2026

Study completion Mar 3, 2029

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
Collaborators
Hoffmann-La Roche
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors

Conditions

  • Solid Tumors

Interventions

  • HS-20110Drug

    HS-20110 will be administered by intravenous infusion in 21 day or 28 day dosing cycles.

  • HS-20110Drug

    The recommended dose from the dose-escalation stage and other potential doses will be further explored. HS-20110 for will be administered by intravenous infusion at selected dose levels, administered in 21 day or 28 day dosing cycles.

  • HS-20110 in combination with bevacizumab, 5-fluorouracil (5-FU), and leucovorin.Drug

    HS-20110 will be administered by intravenous infusion on a Q2W schedule at the dose level determined by the SRC in combination with the standard-of-care regimen in 28 days dosing cycles.

  • HS-20110 in combination with bevacizumab, 5-FU, and leucovorin.Drug

    HS-20110 will be administered by intravenous infusion at selected dose levels and schedules in combination with the standard-of-care regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) or maximum applicable dose (MAD)Time frame: From day 1 to one months after the last dose in Phase 1a
  2. Objective response rate (ORR) as per RECIST v1.1Time frame: From screening to 2 months after the last dose

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • BRCR Medical Center INC

    Tamarac, Florida · Recruiting

  • Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana · Recruiting

  • Carolina BioOncology Institute

    Huntersville, North Carolina · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • SUN YAT-SEN University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.